advertisement
Abstract #98852 Published in IGR 22-4
Posterior scleral contraction to treat myopic traction maculopathy at different stages
Zhu S; Xue A; Li H; Ye J; Pan A; Zheng J; Xu GAmerican journal of translational research 2022; 14: 389-395
OBJECTIVE: We aimed to evaluate anatomical and functional outcomes and determine posterior scleral contraction (PSC) timing in treating myopic traction maculopathy (MTM). METHODS: This is a retrospective study of MTM patients undergoing PSC with genipin cross-linked strip at a single hospital site. Differences in demographic and clinical characteristics were compared among three groups defined by the MTM staging system. All patients were followed up for at least one year postoperatively. The best-corrected visual acuity (BCVA), macular hole diameter, axial length (AL), optical coherence tomography findings, and the complications were evaluated. Additionally, regression analyses were performed to account for confounders. RESULTS: Sixty-one MTM patients (24 eyes at stage 2, 22 eyes at stage 3, and 18 eyes at stage 4) were included. The macular holes were closed in 16 eyes (66.7%), 13 eyes (59.0%), and 11 eyes (61.1%) at stage 2, stage 3, and stage 4, respectively. PSC improved the BCVA in patients at each stage (all < 0.05). Postoperative BCVA at stage 2 was significantly better than that at stage 4 ( = 0.0069). Preoperative BCVA was associated with postoperative BCVA ( < 0.001). Preoperative AL (OR 0.676, 95% CI 0.480 to 0.951, = 0.025), AL shortening amount (OR 5.129, 95% CI 1.974 to 13.327, = 0.001) and macular hole diameter (OR 1.003, 95% CI 1.000 to 1.006, = 0.030) were associated with macular hole closure. CONCLUSIONS: PSC is safe and effective in treating MTM at different stages. Early PSC intervention will have more significant visual benefits.